Robert W. Baird Keeps Their Buy Rating on DaVita

By Jason Carr

In a report released yesterday, Whit Mayo from Robert W. Baird reiterated a Buy rating on DaVita (NYSE: DVA), with a price target of $95. The company’s shares closed yesterday at $80.03, close to its 52-week high of $80.71.

According to TipRanks.com, Mayo is a 3-star analyst with an average return of 2.1% and a 51.8% success rate. Mayo covers the Services sector, focusing on stocks such as Encompass Health Corporation, Fresenius Medical Care Corp, and Quest Diagnostics Inc.

Currently, the analyst consensus on DaVita is Moderate Buy and the average price target is $87.33, representing a 9.1% upside.

In a report issued on January 4, Merrill Lynch also upgraded the stock to Buy with a $85 price target.

The company has a one-year high of $80.71 and a one-year low of $52.51. Currently, DaVita has an average volume of 2.27M.

Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DaVita, Inc. engages in the provision of medical care services. It operates through the following business segments: Kidney Care and HealthCare Partners. The Kidney Care segment focuses on the delivery of dialysis services to patients with chronic kidney failure and end stage renal disease.